Clover Biopharmaceuticals

Public

Shanghai, ShanghaiBiotechhttps://www.cloverbiopharma.com

Clover Biopharmaceuticals is now publicly traded

The data on this page reflects Clover Biopharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Follow-on Offering

Apr 29, 2026

Total Funding Raised

$3.64M

Company Overview

Clover Biopharmaceuticals (HKG: 02197) is a biotechnology company focused on creating innovative vaccines and biologic therapies for infectious diseases, cancer, and autoimmune disorders.

Sector

Biotech

AI Layer

Non-AI

Keywords

Trimer-Tag technology platformprotein-based subunit vaccinesinfectious disease vaccine developmentrespiratory vaccinesCOVID-19 vaccineRSV vaccine candidategovernment vaccine supply agreementsin-house GMP biomanufacturingcovalently-trimerized fusion proteinsquadrivalent seasonal influenza vaccineCOVAX facility vaccine supplierthrombopoietin receptor agonist

Clover Biopharmaceuticals Comparables

Compare Clover Biopharmaceuticals with similar companies based on industry and business-model similarity.

No public comparables are available for Clover Biopharmaceuticals. Request access to learn about comparables coverage.

Request access

Clover Biopharmaceuticals Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Follow-on Offering	Apr 29, 2026

View all Funding Rounds

Clover Biopharmaceuticals Filings

Explore SEC and related filing metadata, where available.

Clover Biopharmaceuticals filings preview — column headings only; records require access
Type	Date	Amount Offered	Amount Sold	Filing	Pages	Download

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersShanghai, Shanghai

Employee Range158

Year Founded2007

Last FundingApr 29, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?